Semisolid systems containing propolis for the treatment of periodontal disease:: In vitro release kinetics, syringeability, rheological, textural, and mucoadhesive properties
Semisolid systems containing propolis for the treatment of periodontal disease:: In vitro release kinetics, syringeability, rheological, textural, and mucoadhesive properties
复制标题
DOI：
10.1002/jps.20843
复制
发表时间：
2007-08-01
影响因子：
3.8
通讯作者：
Lara, Elza H. G.
中科院分区：
文献类型：
--
作者：
Bruschi, Marcos L.;Jones, David S.;Lara, Elza H. G.
含有泊洛沙姆 407 (P407)、卡波姆 934P (C934P) 和蜂胶提取物 (PE) 的配方设计用于治疗牙周病。测定了制剂的胶凝温度、体外药物释放、流变学、硬度、可压缩性、粘附性、粘膜粘附性和可注射性。蜂胶从配方中的释放是通过聚合物链松弛现象来控制的。制剂表现出假塑性流动和低程度的触变性或流变性。在大多数样品中，增加C934P含量的浓度显着增加了5℃时的储能模量(G')、损耗模量(G'')和动态粘度(n')，G''超过了G'。在 25 和 37 摄氏度下，每种配方的 n' 取决于振荡频率。配方表现出热响应行为，在室温下为液体，在 34-37 摄氏度下为凝胶。增加 C934P 含量或温度可显着提高配方硬度、可压缩性和粘合性。在含有 15% P407 (w/w) 和 0.25% C934P (w/w) 的配方中注意到最大的粘膜粘附力。所有制剂的可注射性值的工作相似并且在易于施用方面非常理想。这些制剂中获得的数据表明在牙周炎治疗中具有潜在的有用作用，并表明它们值得临床评估。 (c) 2007 年 Wiley-Liss, Inc.
Formulations containing poloxamer 407 (P407), carbopol 934P (C934P), and propolis extract (PE) were designed for the treatment of periodontal disease. Gelation temperature, in vitro drug release, rheology, hardness, compressibility, adhesiveness, mucoadhesion, and syringeability of formulations were determined. Propolis release from formulations was controlled by the phenomenon of relaxation of polymer chains. Formulations exhibited pseudoplastic flow and low degrees of thixotropy or rheopexy. In most samples, increasing the concentration of C934P content significantly increased storage modulus (G'), loss modulus (G ''), and dynamic viscosity (n') at 5 degrees C, G '' exceeded G'. At 25 and 37 degrees C, n' of each formulation depended on the oscillatory frequency. Formulations showed thermoresponsive behavior, existing as a liquid at room temperature and gel at 34-37 degrees C. Increasing the C934P content or temperature significantly increased formulation hardness, compressibility, and adhesiveness. The greatest mucoadhesion was noted in the formulation containing 15% P407 (w/w) and 0.25% C934P (w/w). The work of syringeability values of all formulations were similar and very desirable with regard to ease of administration. The data obtained in these formulations indicate a potentially useful role in the treatment of periodontitis and suggest they are worthy of clinical evaluation. (c) 2007 Wiley-Liss, Inc.